Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06271291 · ClinicalTrials.gov registry record

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

A clinical trial of Pancreatic Carcinoma, sponsored by Mayo Clinic.

Recruiting
Registry status
30,000
Enrollment target
7
Study locations

NCT06271291 is a study of Pancreatic Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 30,000 participants, above the 1,818-participant average among 18 other Pancreatic Carcinoma trials with a reported enrollment target (1550% higher). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06271291, a study of Pancreatic Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
30,000 participants
Enrollment target
7
Study locations

Study Summary

This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.

Conditions Studied

Interventions

  • OTHER Non-Interventional Study

Study Locations (7)

Arizona

  • HonorHealth Research Institute - Scottsdale

Georgia

  • Piedmont Healthcare - Atlanta

Illinois

  • OSF Saint Francis Medical Center - Peoria

Minnesota

  • Mayo Clinic in Rochester - Rochester

Nebraska

  • University of Nebraska Medical Center - Omaha

Oregon

  • Oregon Health & Science University - Portland

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 30,000 participants
Start Date 2024-12-12
Est. Completion 2029-11-01

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT06271291

The ClinicalTrials.gov registry entry for NCT06271291 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,818-participant average among 18 other Pancreatic Carcinoma trials with a reported enrollment target (1550% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.

NCT06271291 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT06271291 about?

NCT06271291 is a clinical study titled "Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts". This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.

What is the current status of trial NCT06271291?

This trial is currently recruiting. The enrollment target is 30,000 participants. The study started on 2024-12-12. Estimated completion is 2029-11-01.

What conditions does trial NCT06271291 study?

This clinical trial studies the following conditions: Pancreatic Carcinoma.

What interventions are being tested in trial NCT06271291?

The interventions under investigation include: Non-Interventional Study (OTHER).

Who is sponsoring clinical trial NCT06271291?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06271291 being conducted?

This trial has 7 study locations across Arizona, Georgia, Illinois, Minnesota, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.